R&D Efficiency: Big Pharma Overview

Explore R&D investment and innovation output across leading pharmaceutical companies through an interactive data visualizer.

R&D Efficiency: Big Pharma Overview

Explore R&D investment and innovation output across leading pharmaceutical companies through an interactive data visualizer.
Cyntegrity logo – Risk-Based Quality Management Solutions

Understanding R&D Efficiency Through Data

The eyesON R&D Efficiency: Big Pharma Overview visualizer presents a clear, data-focused view of how R&D spending translates into regulatory outcomes across major publicly traded pharmaceutical companies.

By connecting R&D investment levels with FDA-approved New Molecular Entities (NMEs) and Biologic License Applications (BLAs), the tool illustrates how efficiently organizations convert research spending into approved innovation. The result is a comparative view of R&D Return on Investment (ROI) across the industry.

Rather than relying on static tables or isolated metrics, the visualizer allows users to explore the relationship between strategic investment and regulatory success in a single interactive environment.

What You Can Do With the Visualizer

The visualizer supports analysis of pharmaceutical innovation performance at a company level.

R&D Spend vs. Regulatory Output

See how R&D expenditures relate to the number of FDA-approved NMEs and BLAs across leading pharma companies.

Company-Level Innovation Profiles

Explore how individual organizations perform in terms of R&D efficiency and regulatory productivity.

ROI-Oriented Insights

Understand differences in R&D return by visualizing investment patterns alongside approval outcomes.

Designed for Insight, Not Just Numbers

The eyesON R&D Efficiency visualizer is built to reveal patterns behind innovation performance. By presenting data visually, it helps users move beyond raw figures and see how investment strategies align with regulatory achievements across the industry.

It is equally relevant for professionals refining R&D decision-making and for anyone interested in understanding how large pharmaceutical organizations translate research budgets into approved therapies.

Where Do the Data and Methods Come From?
The visualizer uses publicly available financial data from sec.gov and gurufocus.com, combined with FDA approval data for NMEs and BLAs from fda.gov. More details on data sources, extraction methods, and the analytical approach are available in the Data Definition tab within the app.

Part of the eyesON Interactive Visualizer Series

R&D Efficiency: Big Pharma Overview is part of eyesON, a series of free interactive data visualizers developed by Cyntegrity. The eyesON series reflects Cyntegrity’s commitment to sharing data analytics capabilities and clinical research expertise with the wider research community. Each visualizer is designed to make complex industry data easier to explore, compare, and apply in real-world decision-making.

Interested in exploring more interactive data visualizers from Cyntegrity? You can discover the full eyesON collection through the platform. Explore More Interactive Visualizers…

Explore Our Visualizer

See how other datasets can sharpen signal awareness and decision-making.

Stay Informed with Us

Risk-based quality management in 2026

Risk-based quality management in 2026: how ICH E6(R3) defines RBQM, where practice diverges, and what regulators now expect in clinical trials....
Diagram illustrating the FDA Total Product Lifecycle (TPLC) management approach for AI and machine learning devices, showing a continuous cycle of design, validation, submission, monitoring, and update.

FDA AI Guidance 2025 Interactive Visualizer

Explore how FDA’s 2025 AI guidance shapes lifecycle oversight for AI-enabled medical software through interactive regulatory scenarios....

Media Inquiries

Need a quote, speaker, or more info about Cyntegrity? Reach out directly to our media contact for timely assistance.

Let’s Talk RBQM @ SCOPE Summit! Visit us at Booth #615

Cyntegrity logo – Risk-Based Quality Management Solutions
Picture of Artem Andrianov, PhD

Artem Andrianov, PhD

CEO & Founder

Picture of Dr. Johann Proeve

Dr. Johann Proeve

Chief Scientific Officer

Picture of David Lacagnina

David Lacagnina

Chief Business Officer

Picture of Sven Cohadzic

Sven Cohadzic

Project Manager